XZXiao Zhong

Xiao Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiao Zhong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of an Epigenetic Signature for Coronary Heart Disease in Postmenopausal Women's PBMC DNA

    by Xiao Zhong, Ziguang Song, Pingping Gao, Mingyang Li, Zhongping Ning, Xiang Song

    Menopause is accompanied with an increased risk of cardiovascular disease. DNA methylation may have a significant impact on postmenopausal women's development of coronary heart disease. DNA methylation alterations in peripheral blood mononuclear cells (PBMCs) from women with coronary heart disease and healthy controls were detected using the Illumina Infinium MethylationEPIC BeadChip platform in this work. We employed Sangerbox technology and the GO and KEGG databases to further study the pathogenesis of coronary heart disease in postmenopausal women. After that, we used functional epigenetic module analysis and Cytoscape to remove the hub genes from the protein-protein interaction networks. Five genes (FOXA2, PTRD, CREB1, CTNAP2, and FBN2) were the hub genes. Lipid accumulation, endothelial cell failure, inflammatory responses, monocyte recruitment and aggregation, and other critical biological processes were all influenced by these genes. Finally, we employed methylation-specific PCR to demonstrate that FOXA2 was methylated at a high level in postmenopausal women with coronary heart disease. To better understand coronary heart disease in postmenopausal women's molecular mechanisms, our study examine the major factors contributing to the state of DNA methylation modification, which will help discover novel diagnostic tools and treatment options.


  • Survival motor neuron protein protects H9c2 cardiomyocytes from hypoxia‐induced cell injury by reducing apoptosis

    by Xiao Zhong, Ziguang Song, Xiang Song

    Background: Hypoxia induces cell injury in cardiomyocytes and leads to the development of cardiovascular diseases. The survival motor neuron protein (SMN) is a crucial ubiquitous protein whose functional deficiency causes motor neuron loss seen in spinal muscular atrophy. SMN has shown protective effects on the cardiovascular system and the aim of the present study was to investigate the cardioprotective effects of SMN on hypoxia‐induced cell injury.Methods: Cobalt chloride (CoCl2) was used to induce chemical hypoxia in H9c2 cardiomyocytes. Cell proliferation was determined by the MTT assay and the mRNA levels of SMN were evaluated by real‐time polymerase chain reaction. The protein expression levels of SMN, hypoxia‐inducible transcription factor 1α (HIF‐1α), and apoptosis‐related proteins, such as cytochrome c (Cyt c), B cell lymphoma‐2 (Bcl‐2), Bcl‐2 associated X protein (Bax), and cleaved caspase‐3 were evaluated by western blot analysis. Cell apoptosis was analysed using annexin V/propidium iodide (PI) staining.Results: Treatment with CoCl2 significantly reduced H9c2 cell viability; the level of HIF‐1α, which is a hypoxia‐related indicator increased whereas the expression of SMN protein decreased. Hypoxia also induced cardiomyocyte apoptosis, indicated by reduced Bcl‐2 expression and elevated cleaved caspase‐3, Bax, and cytochrome c levels. Interestingly, SMN, which is a neuron protection factor, ameliorated CoCl2‐induced cell damage by reducing cardiomyocyte apoptosis through upregulation of Bcl‐2 and inhibition of cytochrome c, cleaved caspase‐3, and Bax expression.Conclusion: Survival motor neuron prevents hypoxia‐induced cell apoptosis through inhibition of the mitochondrial apoptotic pathway, and thereby exerts a protective effect on H9c2 cardiomyocytes.


  • Open Access

    The role of galectin‐3 in heart failure and cardiovascular disease

    by Xiao Zhong, Xiaoqian Qian, Guangping Chen, Xiang Song

    Summary: Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.


  • Open Access

    Determination of RHD zygosity using real-time quantitative PCR

    by Yun Li, Bernhard Zimmermann, Xiao Yan Zhong, Anurag Gupta, Wolfgang Holzgreve, S. Hahn

    At present RHD incompatibility is still an obstetric problem despite prophylactic treatment. A very welcome recent technical advance has now made it possible to determine the foetal RHD status in a non-invasive risk-free manner using cell free foetal DNA in maternal plasma. In some cases, however, where there is a high risk that the foetus may be affected by HDN (haemolytic disease of the newborn), it may be of interest to determine whether the father is hetero- or homozygous for the RHD gene, since in the former instance there is only a 50% chance that the pregnancy is affected. It has recently been shown that quantitative PCR assays, in particular real-time Taqman PCR, can be used to determine the RHD gene dosage, and also to determine foetal aneuploidies. We demonstrate that the same real-time Taqman PCR assay we had previously developed for non-invasive analysis of the foetal RHD gene and the foetal Y chromosome from maternal plasma can be used to determine the paternal RHD genotype.